Side-by-side comparison of AI visibility scores, market position, and capabilities
Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
$500M Series D at $11B valuation (Feb 2026) — largest voice AI funding round ever. $330M ARR; 1M+ developers using the API. Enterprise customers: Deutsche Telekom, Revolut, Meta, Salesforce. Voices in 32 languages; real-time cloning from 1 second of audio.
ElevenLabs was founded in 2022 by Piotr Dabkowski and Mati Staniszewski, two former Google and Palantir engineers who set out to break the language barrier using AI voice technology. The company specializes in AI-powered voice synthesis, cloning, and dubbing, enabling developers and enterprises to generate human-quality speech in over 30 languages. Its core technology combines deep learning models trained on massive speech datasets to produce natural-sounding voices indistinguishable from real humans.\n\nElevenLabs offers a suite of products including its flagship text-to-speech API, voice cloning tools, and an AI dubbing platform that localizes video content while preserving the speaker's original voice. Its products target a broad audience—from indie developers building audio apps to large enterprises deploying voice interfaces at scale. Key differentiators include ultra-low latency streaming synthesis, fine-grained voice customization, and a growing library of pre-built AI voices across accents and styles.\n\nElevenLabs has grown rapidly, surpassing $330M in annualized revenue and serving over 1 million developers. Enterprise clients include Deutsche Telekom, Spotify, and leading media companies. In February 2026, the company closed a $500M Series D at an $11B valuation, cementing its position as the market leader in AI voice. Its APIs power podcasts, audiobooks, video games, and customer service bots worldwide, making ElevenLabs the default infrastructure layer for AI-generated audio.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.